Compare SABR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | ZVRA |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 472.9M |
| IPO Year | 2014 | 2015 |
| Metric | SABR | ZVRA |
|---|---|---|
| Price | $1.73 | $10.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 5.0M | 665.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 159.21 |
| EPS | 1.34 | ★ 1.35 |
| Revenue | ★ $3,866,956,000.00 | $106,470,000.00 |
| Revenue This Year | $7.15 | $37.27 |
| Revenue Next Year | $3.40 | $53.42 |
| P/E Ratio | ★ $1.31 | $7.65 |
| Revenue Growth | 7.46 | ★ 350.91 |
| 52 Week Low | $0.81 | $6.85 |
| 52 Week High | $3.46 | $13.16 |
| Indicator | SABR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 64.60 |
| Support Level | $1.72 | $8.29 |
| Resistance Level | $1.98 | $11.19 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 85.71 | 88.68 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.